

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

SEED Innovations Ltd / AIM: SEED / Sector: Closed End Investments

22 May 2025

**SEED Innovations Limited**  
("SEED" or the "Company")

**Investee Company Update: Juvenescence Ltd**

*76m fundraising led by Abu Dhabi-based, global tech-enabled healthcare company M42*

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors, is pleased to announce that its portfolio company, Juvenescence, has today announced the first closing of its Series B-1 fundraising, securing a total of 76m in a round led by Abu Dhabi-based, global tech-enabled healthcare company M42.

SEED holds 128,205 ordinary shares in Juvenescence, representing approximately 0.55% of Juvenescence's issued share capital prior to this raise. SEED's investment in Juvenescence is carried at approximately £2.4 Million and this valuation is not affected by this fundraising.

**Key Highlights:**

- Juvenescence has raised 76m at the First Close of its Series B-1 fundraising, led by cornerstone investor M42, along with follow-on investments from existing investors
- Juvenescence recently entered into a wider partnership with M42 to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases.
- The financing will enable Juvenescence to progress its portfolio of therapeutics into clinical development and deliver critical clinical readouts for its core medicine pipeline.
- The second close of the Series B-1 is anticipated to be completed in Q3 2025.

Juvenescence's full announcement can be accessed here: <https://www.globenewswire.com/news-release/2025/05/21/3085420/0/en/Juvenescence-closes-76m-first-tranche-of-Series-B-1-financing-led-by-Abu-Dhabi-s-M42-alongside-strategic-partnership.html>

**- Ends -**

For further information on the Company please visit: [www.seedinnovations.co](http://www.seedinnovations.co) or contact:

Ed McDermott	SEED Innovations Ltd	E: <a href="mailto:info@seedinnovations.co">info@seedinnovations.co</a>
Lance de Jersey		

James Biddle	Beaumont Cornish Limited,	T: (0)20 7628 3396
Roland Cornish	Nomad	

Isabella Pierre	Shard Capital Partners LLP	T: (0)20 7186 9927
Damon Heath	Broker	

Ana Ribeiro	St Brides Partners Ltd.	E: <a href="mailto:seed@stbridespartners.co.uk">seed@stbridespartners.co.uk</a>
-------------	-------------------------	---

**NOTES****Seed Innovations Ltd**

Seed Innovations Ltd is an AIM quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors. Its strategy focuses on identifying early-stage opportunities with upcoming investment catalysts, alongside more mature investments providing near-term liquidity. With a portfolio of such investments and cash reserves, the Company is agile and poised to capitalise swiftly on new investment opportunities.

**Juvenescence**

Juvenescence is a therapeutics and development company, currently creating multiple therapeutics focused on improving and extending human lifespans. The Juvenescence team comprises proven and seasoned experts in drug development, strategy, structure, commercialisation and finance.

The Company's approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life. By focusing on early disease intervention and prevention, Juvenescence are committed to transforming how we age, ensuring that added years are healthy and fulfilling.

**M42**

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialised, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.

Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUAUNRVKUVUAR